Lifescience Intellipedia Pvt. Ltd.
C-89, 1st floor, Sector-65
Noida-201301, India+91-120-4670901-925
info@marketresearch.com| Sr.no | Companies | Revenue (USD Bn) |
|---|---|---|
| 1 | Johnson & Johnson | $56.1bn |
| 2 | Pfizer | $51.75bn |
| 3 | Roche | $49.23bn |
| 4 | Novartis | $47.45bn |
| 5 | Merck & Co. | $46.84bn |
| 6 | Sanofi | $40.46bn |
| 7 | AbbVie | $33.26bn |
| 8 | Takeda | $30.52bn |
| 9 | Shanghai Pharmaceuticals Holding | $26.69bn |
| Sr.no | API | Revenue (USD Bn) |
|---|---|---|
| 1 | Adalimumab | 20.4 |
| 2 | Pembrolizumab | 14.4 |
| 3 | Lenalidomide | 12.2 |
| 4 | Apixaban | 9.2 |
| 5 | Aflibercept | 8.4 |
| 6 | Ustekinumab | 7.9 |
| 7 | Nivolumab | 7.6 |
| 8 | Emtricitabine | 7.3 |
| 9 | Rivaroxaban | 6.9 |
| Sr.no | Merger and Acquisition Company | Deal value (USD Bn) | Date announce |
|---|---|---|---|
| 1 | AstraZeneca/Alexion Pharmaceuticals | $39 | Dec. 12, 2020 |
| 2 | Gilead Sciences/Immunomedics | $21 | Sept. 13, 2020 |
| 3 | Bristol Myers Squibb/MyoKardia | $13.1 | Oct. 5, 2020 |
| 4 | Johnson & Johnson/Momenta Pharmaceuticals | $6.5 | Aug. 19, 2020 |
| 5 | Gilead Sciences/Forty Seven | $4.9 | March 2, 2020 |
| Sr.no | Companies | Revenue (USD Bn) |
|---|---|---|
| 1 | Johnson & Johnson | $56.1bn |
| 2 | Pfizer | $51.75bn |
| 3 | Roche | $49.23bn |
| 4 | Novartis | $47.45bn |
| 5 | Merck & Co. | $46.84bn |
| 6 | Sanofi | $40.46bn |
| 7 | AbbVie | $33.26bn |
| 8 | Takeda | $30.52bn |
| 9 | Shanghai Pharmaceuticals Holding | $26.69bn |